[关键词]
[摘要]
目的 观察荷丹片联合瑞舒伐他汀治疗2型糖尿病合并高脂血症的临床疗效。方法 选择2011年1月—2014年5月在天津市河北区建昌道街社区卫生服务中心就诊的2型糖尿病合并高脂血症患者100例, 随机分为对照组和治疗组, 每组50例。对照组每日晚餐后口服瑞舒伐他汀钙片10 mg/次, 1次/d。治疗组在对照组治疗的基础上饭前30 min口服荷丹片, 2片/次, 3次/d。两组均连续治疗12周。观察两组的临床疗效, 同时比较两组治疗前后胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FPG)、餐后2 h血糖(2hPBG)以及糖化血红蛋白(HbAlc)的变化。结果 治疗后, 对照组和治疗组的总有效率分别为82.0%、94.0%, 两组总有效率比较差异有统计学意义(P<0.05)。治疗后, 两组患者的TG、TC、LDL-C、FPG、2hPG、HbAlc均较治疗前显著下降, HDL-C明显升高, 同组治疗前后差异有统计学意义(P<0.05);且治疗后治疗组这些观察指标的改善程度优于对照组, 两组比较差异具有统计学意义(P<0.05)。结论 荷丹片联合瑞舒伐他汀治疗2型糖尿病合并高脂血症具有较好的临床疗效, 可更好的调节血糖和血脂水平, 且安全性较好, 具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To observe the clinical curative effect of Hedan Tablets combined with rosuvastatin in treatment of type 2 diabetes with hyperlipidemia. Methods Patients (100 cases) with type 2 diabetes with hyperlipidemia in Community Health Service Center of Tianjin Hebei District Jianchang Road from January 2011 to May 2014 were randomly divided into control and treatment groups, and each group had 50 cases. The patients in the control group were po administered with Rosuvastatin Calcium Tablets after dinner, 10 mg/time, once daily. The patients in the treatment group were po administered with Hedan Tablets 30 min before meals on the basis of control group, 2 tablets/time, three times daily. Two groups were treated for 12 weeks. After treatment, the efficacy was evaluated, and the changes of TC, TG, LDL-C, HDL-C, FPG, 2hPBG, and HbAlc in two groups were compared. Results The efficacies in the control and treatment groups were 82.0% and 94.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, TG, TC, LDL-C, FPG, 2hPG, and HbAlc in two groups were significantly reduced, while HDL-C were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Hedan Tablets combined with rosuvastatin has good clinical efficacy in treatment of type 2 diabetes with hyperlipidemia, and can regulate blood sugar and lipid levels with good safety, which has a certain clinical application value.
[中图分类号]
[基金项目]